Resources from the same session
1963O - JCOG1019: An open-label, non-inferiority, randomised phase III study comparing the effectiveness of watchful waiting (WW) and intravesical Bacillus Calmette-Guérin (BCG) in patients (Pts) with high-grade pT1 (HGT1) bladder cancer with pT0 on the second transurethral resection (TUR) specimen
Presenter: Hiroshi Kitamura
Session: Proffered Paper session 2: GU, non-prostate
Resources:
Abstract
Slides
Webcast
1960O - Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial
Presenter: Jorgen Bjerggaard Jensen
Session: Proffered Paper session 2: GU, non-prostate
Resources:
Abstract
Slides
Webcast
LBA84 - TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4)
Presenter: Andrea Necchi
Session: Proffered Paper session 2: GU, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1963O, 1960O and LBA84
Presenter: Bogdana Schmidt
Session: Proffered Paper session 2: GU, non-prostate
Resources:
Slides
Webcast
Q&A
Session: Proffered Paper session 2: GU, non-prostate
Resources:
Webcast
1961O - Nivolumab plus chemoradiotherapy in patients with non-metastatic muscle-invasive bladder cancer (nmMIBC), not undergoing cystectomy: A phase II, randomized study by the Hellenic GU Cancer Group
Presenter: Andromachi Kougioumtzopoulou
Session: Proffered Paper session 2: GU, non-prostate
Resources:
Abstract
Slides
Webcast
1962O - Health-related quality of life from the CheckMate 901 trial of nivolumab as first-line therapy for unresectable or metastatic urothelial carcinoma
Presenter: Jens Bedke
Session: Proffered Paper session 2: GU, non-prostate
Resources:
Abstract
Slides
Webcast
Q&A
Session: Proffered Paper session 2: GU, non-prostate
Resources:
Webcast